Tizanidine: Nursing Drug Guide, CYP1A2 Interactions & Hold Rules
Healthcare medication guide: center care on CYP1A2 interaction risk, because strong inhibitors can sharply raise tizanidine exposure and trigger hypotension, bradycardia, and excessive sedation; keep food timing and capsule/tablet formulation consistent, and follow liver monitoring plus hold-escalation rules each shift.
Tizanidine is contraindicated with strong CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine. Co-administration can markedly increase tizanidine exposure with profound hypotension, bradycardia, and dangerous sedation. Also avoid moderate or weak CYP1A2 inhibitors when possible, and hold doses when blood pressure drops, arousal worsens, or liver injury cues appear.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, verify no CYP1A2 inhibitor was added, trend blood pressure and arousal, and keep food timing plus formulation consistent. If hypotension, bradycardia, severe somnolence, or liver-injury signs appear, hold tizanidine and escalate immediately.
Most common brand names
Common brand name: Zanaflex. Generic tizanidine tablets and capsules are also used in adult spasticity care settings.
Why we give it — Indications
Per the Zanaflex DailyMed label, tizanidine is indicated for management of spasticity in adults, including situations such as multiple sclerosis and spinal cord injury where spasms limit movement and comfort.
Tizanidine is not a cure for the underlying neurologic disease. Bedside goals focus on reducing problematic tone and muscle spasms while preventing interaction-related hypotension and excessive sedation.
| Use | Clinical detail |
|---|---|
| Approved indication | Management of spasticity in adults |
| Setting | Intermittent oral dosing tied to daytime activity needs |
| Nursing emphasis | Balance symptom relief with hemodynamic and sedation safety |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Tizanidine is a central alpha-2 adrenergic agonist that reduces spasticity. The same central effects that reduce tone can also lower blood pressure and increase sedation burden, especially when metabolism is inhibited by CYP1A2-interacting drugs.
Dosing overview
Use label-based titration and conservative adjustment in renal or hepatic impairment. Keep timing and formulation consistent to avoid avoidable exposure swings.
| Clinical scenario | Label-directed nursing implication |
|---|---|
| CrCl < 25 mL/min | Use lower individual doses; if additional effect is needed, increase individual dose instead of dosing frequency |
| Hepatic impairment | Use lower individual doses and monitor closely for adverse effects |
| Discontinuation | Taper slowly by 2-4 mg/day to reduce withdrawal risk |
| Missed dose | Do not double up; resume schedule per order and clinical status |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Perform complete medication reconciliation before first dose and after any new order
- Screen for CYP1A2 inhibitors, especially ciprofloxacin and fluvoxamine
- Review avoidance of moderate or weak CYP1A2 inhibitors including famotidine, cimetidine, oral contraceptives, and acyclovir when clinically possible
- Check baseline blood pressure using standardized blood pressure measurement technique before dosing and after dose changes
- Assess baseline orthostatic risk and complete fall risk assessment
Contraindications
- Concomitant use with strong CYP1A2 inhibitors
- Hypersensitivity to tizanidine
Interaction-focused administration risks
| Medication group | Risk | Nursing action |
|---|---|---|
| Strong CYP1A2 inhibitors | Contraindicated: major tizanidine exposure increase with hypotension, bradycardia, and severe sedation | Do not administer; escalate to prescriber and pharmacy immediately |
| Moderate/weak CYP1A2 inhibitors | Potential exposure increase and adverse hemodynamic/CNS effects | Avoid when possible; if unavoidable, intensify monitoring and verify individualized plan |
| Other CNS depressants such as baclofen and morphine | Additive sedation and safety-event risk | Reassess arousal and respiratory status before each scheduled dose |
On a small screen, swipe or scroll sideways to see the full table.
Administration
- Give oral doses exactly as ordered and tied to timing of spasticity-related activity needs
- Keep administration consistent with or without food for a given patient plan
- Do not switch between capsules and tablets in fed conditions without prescriber review; the label states they are not bioequivalent when fed
- Integrate mobility and comfort checks with routine pain assessment documentation
Expected therapeutic response
- Reduced frequency or intensity of spastic episodes with improved functional comfort
- Stable blood pressure and heart rate after routine doses
- Arousal preserved enough for safe participation in care and activities
Red flags — Stop and act
- Symptomatic hypotension, syncope, or bradycardia after dosing
- New or worsening dizziness with unstable gait or near-falls
- Marked sedation or new confusion that impairs safety checks
- Possible liver injury signs such as rising enzymes or clinical jaundice
- Withdrawal pattern after abrupt stop: rebound hypertension, tachycardia, or worsened hypertonia
Adverse effects
Label-reported adverse effects with incidence over 10% include dry mouth, somnolence, asthenia, and dizziness. Serious warnings include hypotension, syncope, liver injury, hallucinations, and withdrawal effects after abrupt discontinuation.
| Effect | Clinical significance | Nursing response |
|---|---|---|
| Dry mouth, somnolence, asthenia, dizziness | Common and can reduce oral intake, mobility safety, and participation in care | Document symptom burden and reassess timing/dose impact |
| Hypotension and syncope | Can progress to injury or hemodynamic instability | Hold next dose and escalate for medication review |
| Liver injury | Potentially serious hepatotoxic pattern | Follow ordered liver monitoring and report significant abnormalities |
| Hallucinations | Neuropsychiatric adverse effect requiring reassessment | Protect safety and notify prescriber promptly |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
There is no specific antidote for tizanidine overdose in the label. Toxicity may resemble clonidine effects. Management is supportive with airway protection and cardiovascular/respiratory monitoring; dialysis is unlikely to be effective.
For suspected overdose, activate emergency response and contact local poison control or toxicology services per facility protocol while supportive care is initiated.
Look-alike / sound-alike and error prevention
- Verify newly ordered anti-infectives before administration to prevent contraindicated combination errors
- Do not auto-continue home tizanidine when a strong CYP1A2 inhibitor is started unless provider and pharmacy clear the plan
- Confirm taper instructions before discontinuation to avoid rebound withdrawal events
Practical bedside notes
| Bedside focus | How to operationalize |
|---|---|
| First-shift check | Confirm no contraindicated CYP1A2 drug was started overnight |
| Hemodynamic trend | Compare pre-dose and post-dose vitals and mental status every shift |
| Functional safety | Coordinate mobility and transfer assistance when sedation risk is elevated |
| De-prescribing handoff | Communicate taper need clearly at transfer and discharge |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Higher-risk issue |
|---|---|
| CrCl < 25 mL/min | Reduced clearance; start with lower individual doses and avoid frequency escalation |
| Hepatic impairment | Use lower individual doses; monitor closely for adverse effects and liver injury |
| Patients with polypharmacy | Interaction risk rises when new CYP1A2 inhibitors are added after admission |
| Pregnancy | Animal data indicate fetal harm; weigh benefit-risk with prescriber |
| Lactation | No human milk data in label; coordinate individualized counseling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure and heart rate trends pre-dose and post-dose
- Sedation level, responsiveness, and mobility safety
- Liver monitoring with baseline and post-titration testing per label: baseline and one month after maximum dose is achieved using ALT
Document
- Total daily dose and any titration changes
- Food/formulation consistency plan (tablet or capsule and meal timing pattern)
- Interaction checks, hold events, and provider-pharmacist notifications
Patient teaching
- Take exactly as prescribed and do not self-escalate doses
- Report faintness, very slow pulse, severe sleepiness, or hallucinations promptly
- Keep food timing consistent and avoid unplanned switch between tablet and capsule with meals
- Do not stop abruptly; taper instructions prevent rebound hypertension and tachycardia
The Hold Rule
Do not administer and contact prescriber/pharmacist when:
- Strong CYP1A2 inhibitor appears on MAR (including ciprofloxacin or fluvoxamine)
- New symptomatic hypotension or bradycardia after a recent dose
- Marked somnolence that interferes with airway protection or safe ambulation
- Clinically significant liver-injury concern pending provider review
- Withdrawal risk after abrupt discontinuation without taper plan
Clinical practice integration and workflow
Tizanidine safety failures usually happen when new medications are added but interaction checks are not repeated at the point of administration. Build a repeatable workflow around interaction screening, hemodynamic trends, and liver follow-up.
1. Admission and every-order-update check
- Reconcile all medication changes against CYP1A2 interaction risk before each first dose
- Highlight high-risk combinations in shift handoff and bedside report
2. Bedside risk bundle
Not a universal high-alert medication, but interaction-triggered hypotension and sedation can become rapidly dangerousTreat new anti-infective starts as a hard stop for interaction review before the next tizanidine dose.
3. Escalation decision points
- If blood pressure drops with worsening somnolence, hold and escalate immediately
- If taper was omitted at discontinuation, call for an urgent taper plan
- If new liver concerns emerge after dose increases, pause and verify monitoring orders
🧠 Quick mental checklist
- Any strong CYP1A2 inhibitor newly added today?
- Dose within labeled individual and daily limits?
- Food timing and formulation plan consistent?
- Post-dose blood pressure and sedation reassessed?
- If stopping, is a 2-4 mg/day taper documented?
Tizanidine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for tizanidine using a tabbed case panel (MAR, labs, vitals, nursing notes), then work through priority action, interaction cues, trend evaluation, food/formulation cloze, liver monitoring, and matrix urgency decisions.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Tizanidine 4 mg PO three times daily for MS-related spasticity
- Ciprofloxacin 500 mg PO twice daily started today for UTI
- 1300 tizanidine dose due in 30 minutes
- Baseline ALT from last week available in chart
- No repeat liver panel yet after recent dose increase
- Renal panel stable this morning
- 0700: BP 122/76, HR 78, alert and conversational
- 1100: BP 94/58, HR 56, drowsy but arousable
- 1230: BP 88/54, HR 52, increasing somnolence
- Patient reports feeling unusually sleepy and lightheaded after morning doses
- No chest pain or shortness of breath reported
- Provider not yet contacted about ciprofloxacin-tizanidine combination
Answer key & rationale
Frequently asked questions
Why are CYP1A2 interactions the top tizanidine danger?
The Zanaflex label warns that strong CYP1A2 inhibitors can markedly raise tizanidine exposure. This can lead to severe hypotension, bradycardia, and excessive sedation, so contraindicated combinations should be treated as hard-stop medication safety events.
What are practical hold rules for bedside nurses?
Hold and escalate when strong CYP1A2 inhibitors are present, when symptomatic hypotension or bradycardia occurs, or when sedation impairs safety. Also pause for possible liver injury and verify taper plans before discontinuation.
How should liver monitoring be timed for tizanidine?
The label recommends monitoring aminotransferase levels, including baseline testing and repeat ALT about one month after the maximum dose is reached. Additional testing is guided by symptoms and clinical judgment.
Is there an antidote for tizanidine overdose?
No specific antidote is listed. Management is supportive: airway support, cardiovascular and respiratory monitoring, and protocol-based toxicology escalation. The label notes dialysis is unlikely to be effective.
Does food timing matter with tablets and capsules?
Yes. The label advises consistent administration with respect to food, and it states fed tablets and capsules are not bioequivalent. Avoid unplanned formulation switching when meals are involved.
References
-
U.S. National Library of Medicine. ZANAFLEX (tizanidine hydrochloride) tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60c27d35-7349-4fc6-86ad-70fffdbe3e08
-
U.S. National Library of Medicine. Tizanidine tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01c0d3d3-2373-a1b7-822a-80a66291a248
-
Drugs and Lactation Database (LactMed). Tizanidine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501922/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.